Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis
Authors:
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 519, 141-149
Abstract
No abstract availableKeywords
Funding Information
- Winship Cancer Institute
This publication has 28 references indexed in Scilit:
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCancer Research, 2015
- Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in CancerPLOS ONE, 2012
- Multisite phosphorylation of Erk5 in mitosisJournal of Cell Science, 2010
- Enhancing Mammalian Target of Rapamycin (mTOR)–Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt ActivationCancer Research, 2008
- Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer CellsJNCI: Journal of the National Cancer Institute, 2004
- MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxolOncogene, 2004
- Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, BimJournal of Biological Chemistry, 2003
- Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cellsOncogene, 1999
- Primary Structure of BMK1: A New Mammalian MAP KinaseBiochemical and Biophysical Research Communications, 1995
- Components of a New Human Protein Kinase Signal Transduction PathwayJournal of Biological Chemistry, 1995